NCT06245291

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects With Chronic HBV Infection

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Arbutus Biopharma Corporation · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2a, open-label, multicenter study investigating the safety, tolerability, and antiviral activity of durvalumab administered at targeted times during a 48-week treatment period of imdusiran in virologically-suppressed CHB subjects

Conditions

• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	Imdusiran	subcutaneous injection
DRUG	Durvalumab	intravenous injection

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-08-01
• Completion: 2024-08-01
• First posted: 2024-02-07
• Last updated: 2024-08-12

Locations

22 sites across 8 countries: Georgia, Hong Kong, Poland, Romania, Spain, Taiwan, Thailand, United Kingdom

Regulatory

• FDA-regulated drug study